Vacantes en Ancona, Gran Bretaña

Reports to Vice President, Head of Global Marketing and Commercial Excellence

Location : Europe, full remote

Department : Global AI Acceleration Unit Oncology

We are seeking a highly motivated and experienced AI Prompt Engineer with a strong background in pharmaceutical commercial operations. This role will be pivotal in integrating advanced AI and prompt engineering techniques to optimize commercial strategies, enhance customer engagement, and drive business growth. The ideal candidate will possess 5-7 years of relevant experience, a deep understanding of pharmaceutical commercial roles (such as marketing, sales, market access), and a solid grasp of prompting best practices for various AI models.

Responsibilities

• Collaborate with commercial teams (marketing, sales, market access, medical affairs, etc.) to identify opportunities for AI-driven solutions and process improvements.
• Design, develop, and refine high-quality prompts for generative AI models to support a range of commercial activities, including content creation for marketing campaigns, sales enablement materials, market analysis summaries, and competitive intelligence reports.
• Train and guide commercial colleagues on effective prompt engineering techniques and the ethical use of AI tools.
• Analyze and interpret outputs from AI models, ensuring accuracy, relevance, and alignment with commercial objectives and compliance guidelines.
• Develop and maintain a library of best-practice prompts and use cases tailored to pharmaceutical commercial needs.
• Stay abreast of the latest advancements in AI, prompt engineering, and their applications within the pharmaceutical commercial landscape.
• Work closely with data analysts and IT teams to ensure seamless integration of AI tools with existing commercial platforms and data sources.
• Measure and report on the impact of AI initiatives on commercial effectiveness and efficiency.
• Ensure all AI-driven commercial activities adhere to pharmaceutical industry regulations, ethical guidelines, and company policies.

Qualifications

• Bachelor's or Master's degree in Business, Marketing, Pharmaceutical Sciences, Computer Science, or a related field.
• 5-7 years of experience in the pharmaceutical industry, with a significant portion focused on commercial roles (e.g., product management, marketing, sales operations, market access, medical science liaison).
• Proven experience in developing and optimizing prompts for various AI models (e.g., LLMs, image generation models).
• Solid understanding of AI / ML concepts and the practical applications of generative AI.
• Familiarity with pharmaceutical commercial strategies, data sources, and regulatory requirements.
• Excellent communication, interpersonal, and collaboration skills, with the ability to translate complex AI concepts into understandable terms for non-technical stakeholders.
• Strong analytical and problem-solving abilities.
• Ability to work independently and manage multiple projects in a fast-paced environment.
• Experience with AI ethics and responsible AI practices is a plus.

Menarini Stemline is an equal-opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees

The Company

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.

Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA / CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1 / HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.

In 2022, the company launched the CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.

Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.

LI-PP1

J-18808-Ljbffr